Bendamustine plus Rituximab Versus R‐CHOP as First‐Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study

BACKGROUND. Rituximab plus bendamustine (R‐B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice, many centers still prefer R‐CHOP to R‐B in pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Mondello, Patrizia, Steiner, Normann, Willenbacher, Wolfgang, Cerchione, Claudio, Nappi, Davide, Mauro, Endri, Ferrero, Simone, Cuzzocrea, Salvatore, Mian, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Hematologic Malignancies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896707/
https://ncbi.nlm.nih.gov/pubmed/29317554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0037
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados